Zeroing in on ROS1 rearrangements in non-small cell lung cancer

Clin Cancer Res. 2012 Aug 15;18(16):4222-4. doi: 10.1158/1078-0432.CCR-12-1812. Epub 2012 Aug 2.

Abstract

Rimkunas and colleagues report on the development and validation of an immunohistochemical assay evaluating non-small cell lung cancers (NSCLC) for the presence of ROS1 fusions. The diagnostic was validated in a screen of 556 NSCLCs, identifying 9 (1.6%) tumors with oncogenic ROS1 rearrangements. These patients are candidates for ROS1-targeted therapies.

Publication types

  • Comment

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Animals
  • Carcinoma, Non-Small-Cell Lung / metabolism*
  • Carrier Proteins / metabolism*
  • Golgi Matrix Proteins
  • Humans
  • Lung Neoplasms / metabolism*
  • Membrane Proteins / metabolism*
  • Membrane Transport Proteins
  • Oncogene Proteins, Fusion / metabolism*
  • Protein-Tyrosine Kinases / metabolism*
  • Proto-Oncogene Proteins / metabolism*

Substances

  • Adaptor Proteins, Signal Transducing
  • Carrier Proteins
  • FIG-ROS1 fusion protein, human
  • GOPC protein, human
  • Golgi Matrix Proteins
  • Membrane Proteins
  • Membrane Transport Proteins
  • Oncogene Proteins, Fusion
  • Proto-Oncogene Proteins
  • Protein-Tyrosine Kinases
  • ROS1 protein, human